Gel and Capillary Electrophoresis Compared for Human Proteins
|
By LabMedica International staff writers Posted on 12 May 2021 |

Image: The Capillarys 3 TERA is an automated analyzer based on capillary zone electrophoresis and UV detection for the quantitative analysis of Hba1c, proteins (serum and urine), immunotyping (serum and urine), and carbohydrate deficient transferrin (Photo courtesy of Sebia)
The electrophoresis of serum proteins remains a laboratory cornerstone for the diagnosis and monitoring of patients with plasma cell disorders, such as monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenström macroglobulinemia, and AL amyloidosis.
Gel electrophoresis remains the method used by most clinical laboratories in the USA. However usage of gel electrophoresis is gradually decreasing while that of capillary electrophoresis is increasing. More recently, analysis of liquid media by capillary electrophoresis was developed and applied to the analysis of serum proteins for clinical purposes.
Laboratory Immunologists at The Johns Hopkins School of Medicine (Baltimore, MD, USA) tested all serum samples analyzed by the immunology laboratory over the course of eight days for routine clinical purposes during the months of October and November 2019, totaling 304 sera. There were 160 females (62 ± 16 years, range 19 -95) and 144 males (65 ± 14 years, range 23-97), with no significant difference in age according to sex.
Sera were first ran using the system currently in use, which consists of a thin-layer agarose gel, HYDRAGEL 30 Protein (E) (Sebia, Lisses, France) and the Sebia Hydrasys 2 semi-automated analyzer. Sera were then assayed on the Sebia Capillarys III TERA automated analyzer using CAPI 3 Protein (E) reagents. Serum immunofixation electrophoresis (SIFE) was performed in 214 of the total 304 sera because already ordered by the provider for most cases. Sera were pre-diluted according to the immunoglobulin G, A, and M concentrations, and then ran on the immunofixation system currently in use, which consists of a thin-layer agarose gel (HYDRAGEL IF 2/4, from Sebia) and the Hydrasys 2 semi-automated analyzer.
The scientists reported that Gel and capillary estimated the concentration of albumin, gamma region, and M-spikes nearly perfectly, and that of beta, alpha-2, and alpha-1 regions with excellent correlation. The two systems classified concordantly 268 of 304 sera (88% agreement) as having no, one, or two M-spikes, but differed in the remaining 36 sera (12%). Gel electrophoresis correctly identified M-spikes in 82 of 112 sera that were shown to have monoclonal band(s) by immunofixation (73% sensitivity), and correctly did not reveal M-spikes in 97/102 sera that had no immunofixation bands (95% specificity). Capillary achieved slightly higher sensitivity (85/112, 76%) and slightly lower specificity (94/102, 92%), but the two areas under the ROC curves were nearly identical at 0.84.
The authors concluded that Gel and capillary electrophoresis systems perform similarly to estimate the concentration of serum protein fractions and detect M-spikes. The Capillarys system has the disadvantages of a higher equipment cost and requiring a greater sample volume. On the other hand, Capillarys requires less involvement of laboratory technicians, offers a faster turn-around time, identifies the specimens they are being analyzed, does not depend upon the chemicals needed to stain and destain the gels, and is more amenable to remote reporting. The study was published on April 29, 2021 in the journal Practical Laboratory Medicine.
Related Links:
The Johns Hopkins School of Medicine
Sebia
Gel electrophoresis remains the method used by most clinical laboratories in the USA. However usage of gel electrophoresis is gradually decreasing while that of capillary electrophoresis is increasing. More recently, analysis of liquid media by capillary electrophoresis was developed and applied to the analysis of serum proteins for clinical purposes.
Laboratory Immunologists at The Johns Hopkins School of Medicine (Baltimore, MD, USA) tested all serum samples analyzed by the immunology laboratory over the course of eight days for routine clinical purposes during the months of October and November 2019, totaling 304 sera. There were 160 females (62 ± 16 years, range 19 -95) and 144 males (65 ± 14 years, range 23-97), with no significant difference in age according to sex.
Sera were first ran using the system currently in use, which consists of a thin-layer agarose gel, HYDRAGEL 30 Protein (E) (Sebia, Lisses, France) and the Sebia Hydrasys 2 semi-automated analyzer. Sera were then assayed on the Sebia Capillarys III TERA automated analyzer using CAPI 3 Protein (E) reagents. Serum immunofixation electrophoresis (SIFE) was performed in 214 of the total 304 sera because already ordered by the provider for most cases. Sera were pre-diluted according to the immunoglobulin G, A, and M concentrations, and then ran on the immunofixation system currently in use, which consists of a thin-layer agarose gel (HYDRAGEL IF 2/4, from Sebia) and the Hydrasys 2 semi-automated analyzer.
The scientists reported that Gel and capillary estimated the concentration of albumin, gamma region, and M-spikes nearly perfectly, and that of beta, alpha-2, and alpha-1 regions with excellent correlation. The two systems classified concordantly 268 of 304 sera (88% agreement) as having no, one, or two M-spikes, but differed in the remaining 36 sera (12%). Gel electrophoresis correctly identified M-spikes in 82 of 112 sera that were shown to have monoclonal band(s) by immunofixation (73% sensitivity), and correctly did not reveal M-spikes in 97/102 sera that had no immunofixation bands (95% specificity). Capillary achieved slightly higher sensitivity (85/112, 76%) and slightly lower specificity (94/102, 92%), but the two areas under the ROC curves were nearly identical at 0.84.
The authors concluded that Gel and capillary electrophoresis systems perform similarly to estimate the concentration of serum protein fractions and detect M-spikes. The Capillarys system has the disadvantages of a higher equipment cost and requiring a greater sample volume. On the other hand, Capillarys requires less involvement of laboratory technicians, offers a faster turn-around time, identifies the specimens they are being analyzed, does not depend upon the chemicals needed to stain and destain the gels, and is more amenable to remote reporting. The study was published on April 29, 2021 in the journal Practical Laboratory Medicine.
Related Links:
The Johns Hopkins School of Medicine
Sebia
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








